Mingqin Li - Sino Biopharmaceutica President
| SBMFF Stock | USD 0.42 0.00 0.00% |
President
Ms. Li Mingqin serves as Vice President, Executive Director of Sino Biopharmaceutical Ltd. She is currently a vice president of the Company and a director of Beijing Tide, Chia Tai Shaoyang Orthopedic Hospital and CP Boai Investment Ltd., and is principally responsible for the investment affairs of the Group. Ms. Li graduated from the Faculty of Medicine of Beijing Chinese Medicine University with a Bachelor Degree in medicine. Prior to joining the Company, Ms. Li had worked in SinoJapanese Friendly Hospital and Beijing Chinese Medicine University, engaged in teaching of medicines, development of new medicines and medicine management. During the period from 1992 to 1995, Ms. Li had been engaged in postdoctorate research in the Medicine School of University of Colorado, USA and the Medical College of the University of Massachusetts. Ms. Li joined the Group in March, 1997 and has 35 years of experience in the pharmaceutical industry. since 2015.
| Age | 64 |
| Tenure | 10 years |
| Phone | 852 2802 9886 |
| Web | https://www.sinobiopharm.com |
Sino Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Kyle Wool | Dominari Holdings | 47 | |
| Holly MBA | BioLineRx | 63 | |
| David McClung | Biocardia | 62 | |
| George Avgerinos | Fortress Biotech Pref | 69 | |
| Ella Sorani | BioLineRx | 57 | |
Management Performance
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 |
Sino Biopharmaceutical Leadership Team
Elected by the shareholders, the Sino Biopharmaceutica's board of directors comprises two types of representatives: Sino Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sino. The board's role is to monitor Sino Biopharmaceutica's management team and ensure that shareholders' interests are well served. Sino Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sino Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cheung Cheng, Executive Director and Member of Executive Board Committee | ||
| Fai Chia, Assistant to the Chairman, Personnel Manager | ||
| Wei Ye, Assistant President Deputy General Manager - R&D Department | ||
| Ping Tse, Founder and President Compliance Officer, Executive Director, Member of Executive Board Committee and Member of Nomination Committee | ||
| Mingqin Li, Vice President Director and Deputy General Manager of CTGC and the director of Beijing Tide | ||
| Wun Tse, Assistant to the Chairman | ||
| Zhoushan Tian, Vice President of JCTT and General Manager of NJCTT | ||
| Y Tse, Executive Chairman of the Board | ||
| Hsin Tse, VP, General Manager of Audit Department, Executive Director and Member of Executive Board Committee | ||
| Eric Tse, CEO Director |
Sino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sino Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 18.81 B | |||
| Shares Owned By Insiders | 47.86 % | |||
| Shares Owned By Institutions | 14.86 % | |||
| Price To Earning | 24.17 X | |||
| Price To Book | 2.51 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Sino Pink Sheet
Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.